Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

Summary

The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.

Timeline

Start

2023-09-30

Primary completion

2027-07-15

Completion

2027-07-15

Drugs

Indications